Immuno-oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy), by Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), and by Region - Global Trends, and Forecast till 2025

  • Published On : Mar 2018 |
  • Pages : 171 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Immuno-Oncology Drugs Market - Insights

Immuno-Oncology refers to the use of the body’s natural defences to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. It helps the immune system to recognize and target cancer cells. The therapy facilitates long term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology therapy works against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Introduction of novel immune-oncology therapies with lesser side effects is driving growth of the global immune-oncology drugs market

Improved therapeutic outcomes have led to increasing success rates against cancer, owing to in-depth understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Moreover, immuno-oncology therapies have lesser side effects compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy operates through the immune system of the body and does not harm healthy cells as opposed to conventional therapies such as targeted therapy, chemotherapy, and radiation therapy that affect cancerous as well as healthy cells. Novel immune therapies can restore the ability of the immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a, human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies. Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapies is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy under, which Kymriah and Yescarta are available.

The global immuno-oncology drugs market was valued at US$ 43,084.5 million in 2016 and is expected to witness a robust CAGR of 14.9% over the forecast period (2017 – 2025).

Figure No.1: Global Immuno-Oncology Drugs Market Share, by Region (%), 2016

immuno-oncology drugs market

Source: Coherent Market Insights Analysis (2017)

Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune-oncology drugs market

According to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015. Owing to benefits associated with these therapies, the leading players are actively investing in research and development into this treatment category through various collaborations and individual research studies. For instance, EMD Serono is involved in research and development of immune-oncology drugs and has a few drugs in pipeline such as M7824 (investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug manufacturer and MD Anderson Cancer Center entered into a strategic clinical research collaboration for formers drug Keytruda (Pembrolizumab). Celsee Diagnostics and IncellDx announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immune-oncology research and the company launched an immunotherapy collaboration with Kite Pharma to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015.

However, high cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.

Some major players operating in the immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

Natural immunity system holds superior potential to specifically target and destruct tumors while avoiding harm to the normal healthy tissue along with long term memory to prevent cancer recurrence. Immuno-oncology research has supported the fact that immunity system can effectively identify tumors and can stop or control long term growth of the same through immunosurveillance. However, cancer progression leads to suppression of immunity systems natural functioning wherein immune-oncology therapies play an important role. Advent of innovative immune-oncology therapies such as immune-checkpoint inhibitors, therapeutic cancer vaccines, and CAR-T therapies has spurred leading organizations to actively invest into research and development. However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market.

Market Dynamics

Global Immuno-oncology drugs market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc. and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost growth of the immuno-oncology drugs market.

Key features of the study:

  • This report provides in-depth analysis of global immuno-oncology drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
  • The global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

  • Global Immuno-Oncology Drugs Market, By Drug Type:
    • Immune Checkpoint Inhibitors
      • CTL-4 Checkpoint Inhibitor
        • Iplimumab
      • PD-1 & PD-L1 Checkpoint Inhibitor
        • Nivolumab (Opdivo)
        • Atezolimumab (Tecentriq)
        • Pembrolizumab (Keytruda)
        • Avelumab (Bavencio)
        • Durvalumab (Imfinzi)
    • Monoclonal Antibodies
      • Naked Monoclonal Antibodies
        • Rituximab (Rituxan)
        • Trastazumab (Herceptin)
        • Bevacizumab (Avastin)
        • Others
      • Conjugated Monoclonal Antibodies
        • Radiolabeled Antibodies
          • Ibrotumomab Tiuxetan (Zevalin)
        • Chemo labeled Antibodies
          • Brentixumab Vedotin (Adcetris)
          • Trastuzumab Emtansine (Kadcyla)
        • Bispecific Monoclonal Antibodies
          • Blinatumomab (Blincyto)
    • Cytokine Based Immunotherapy
      • Intron A
      • Proleukin
    • Cancer Vaccines
      • Preventive Vaccines
        • Gardasil
        • Cervarix
      • Treatment Vaccines
        • Sipuleucel-T (Provenge)
    • CAR-T Cell Therapy
      • Kymriah
      • Yescarta
  • Global Immuno-Oncology Drugs Market, By Cancer Type:
    • Non-Small Cell Lung Cancer
    • Acute Myeloid Leukemia
    • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
    • Multiple Myeloma
    • Breast Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Gastric Cancers
    • Glioblastoma
    • Head & Neck Cancers
  • Global Immuno-Oncology Drugs Market, By Geography:
    • North America
      • By Drug Type
        • Immune Checkpoint Inhibitors
          • CTL-4 Checkpoint Inhibitor
            • Iplimumab
          • PD-1 & PD-L1 Checkpoint Inhibitor
            • Nivolumab (Opdivo)
            • Atezolimumab (Tecentriq)
            • Pembrolizumab (Keytruda)
            • Avelumab (Bavencio)
            • Durvalumab (Imfinzi)
        • Monoclonal Antibodies
          • Naked Monoclonal Antibodies
            • Rituximab (Rituxan)
            • Trastazumab (Herceptin)
            • Bevacizumab (Avastin)
            • Others
          • Conjugated Monoclonal Antibodies
            • Radiolabeled Antibodies
              • Ibrotumomab Tiuxetan (Zevalin)
            • Chemo labeled Antibodies
              • Brentixumab Vedotin (Adcetris)
              • Trastuzumab Emtansine (Kadcyla)
            • Bispecific Monoclonal Antibodies
              • Blinatumomab (Blincyto)
        • Cytokine Based Immunotherapy
          • Intron A
          • Proleukin
        • Cancer Vaccines
          • Preventive Vaccines
            • Gardasil
            • Cervarix
          • Treatment Vaccines
            • Sipuleucel-T (Provenge)
        • CAR-T Cell Therapy
          • Kymriah
          • Yescarta
      • By Cancer Type:
        • Non-Small Cell Lung Cancer
        • Acute Myeloid Leukemia
        • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
        • Multiple Myeloma
        • Breast Cancer
        • Ovarian Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Gastric Cancers
        • Glioblastoma
        • Head & Neck Cancers
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Immune Checkpoint Inhibitors
          • CTL-4 Checkpoint Inhibitor
            • Iplimumab
          • PD-1 & PD-L1 Checkpoint Inhibitor
            • Nivolumab (Opdivo)
            • Atezolimumab (Tecentriq)
            • Pembrolizumab (Keytruda)
            • Avelumab (Bavencio)
            • Durvalumab (Imfinzi)
        • Monoclonal Antibodies
          • Naked Monoclonal Antibodies
            • Rituximab (Rituxan)
            • Trastazumab (Herceptin)
            • Bevacizumab (Avastin)
            • Others
          • Conjugated Monoclonal Antibodies
            • Radiolabeled Antibodies
              • Ibrotumomab Tiuxetan (Zevalin)
            • Chemo labeled Antibodies
              • Brentixumab Vedotin (Adcetris)
              • Trastuzumab Emtansine (Kadcyla)
            • Bispecific Monoclonal Antibodies
              • Blinatumomab (Blincyto)
        • Cytokine Based Immunotherapy
          • Intron A
          • Proleukin
        • Cancer Vaccines
          • Preventive Vaccines
            • Gardasil
            • Cervarix
          • Treatment Vaccines
            • Sipuleucel-T (Provenge)
        • CAR-T Cell Therapy
          • Kymriah
          • Yescarta
      • By Cancer Type:
        • Non-Small Cell Lung Cancer
        • Acute Myeloid Leukemia
        • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
        • Multiple Myeloma
        • Breast Cancer
        • Ovarian Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Gastric Cancers
        • Glioblastoma
        • Head & Neck Cancers
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Russia
        • Spain
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Immune Checkpoint Inhibitors
          • CTL-4 Checkpoint Inhibitor
            • Iplimumab
          • PD-1 & PD-L1 Checkpoint Inhibitor
            • Nivolumab (Opdivo)
            • Atezolimumab (Tecentriq)
            • Pembrolizumab (Keytruda)
            • Avelumab (Bavencio)
            • Durvalumab (Imfinzi)
        • Monoclonal Antibodies
          • Naked Monoclonal Antibodies
            • Rituximab (Rituxan)
            • Trastazumab (Herceptin)
            • Bevacizumab (Avastin)
            • Others
          • Conjugated Monoclonal Antibodies
            • Radiolabeled Antibodies
              • Ibrotumomab Tiuxetan (Zevalin)
            • Chemo labeled Antibodies
              • Brentixumab Vedotin (Adcetris)
              • Trastuzumab Emtansine (Kadcyla)
            • Bispecific Monoclonal Antibodies
              • Blinatumomab (Blincyto)
        • Cytokine Based Immunotherapy
          • Intron A
          • Proleukin
        • Cancer Vaccines
          • Preventive Vaccines
            • Gardasil
            • Cervarix
          • Treatment Vaccines
            • Sipuleucel-T (Provenge)
        • CAR-T Cell Therapy
          • Kymriah
          • Yescarta
      • By Cancer Type:
        • Non-Small Cell Lung Cancer
        • Acute Myeloid Leukemia
        • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
        • Multiple Myeloma
        • Breast Cancer
        • Ovarian Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Gastric Cancers
        • Glioblastoma
        • Head & Neck Cancers
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • By Drug Type
        • Immune Checkpoint Inhibitors
          • CTL-4 Checkpoint Inhibitor
            • Iplimumab
          • PD-1 & PD-L1 Checkpoint Inhibitor
            • Nivolumab (Opdivo)
            • Atezolimumab (Tecentriq)
            • Pembrolizumab (Keytruda)
            • Avelumab (Bavencio)
            • Durvalumab (Imfinzi)
        • Monoclonal Antibodies
          • Naked Monoclonal Antibodies
            • Rituximab (Rituxan)
            • Trastazumab (Herceptin)
            • Bevacizumab (Avastin)
            • Others
          • Conjugated Monoclonal Antibodies
            • Radiolabeled Antibodies
              • Ibrotumomab Tiuxetan (Zevalin)
            • Chemo labeled Antibodies
              • Brentixumab Vedotin (Adcetris)
              • Trastuzumab Emtansine (Kadcyla)
            • Bispecific Monoclonal Antibodies
              • Blinatumomab (Blincyto)
        • Cytokine Based Immunotherapy
          • Intron A
          • Proleukin
        • Cancer Vaccines
          • Preventive Vaccines
            • Gardasil
            • Cervarix
          • Treatment Vaccines
            • Sipuleucel-T (Provenge)
        • CAR-T Cell Therapy
          • Kymriah
          • Yescarta
      • By Cancer Type:
        • Non-Small Cell Lung Cancer
        • Acute Myeloid Leukemia
        • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
        • Multiple Myeloma
        • Breast Cancer
        • Ovarian Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Gastric Cancers
        • Glioblastoma
        • Head & Neck Cancers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of LATAM
    • Middle East
      • By Drug Type
        • Immune Checkpoint Inhibitors
          • CTL-4 Checkpoint Inhibitor
            • Iplimumab
          • PD-1 & PD-L1 Checkpoint Inhibitor
            • Nivolumab (Opdivo)
            • Atezolimumab (Tecentriq)
            • Pembrolizumab (Keytruda)
            • Avelumab (Bavencio)
            • Durvalumab (Imfinzi)
        • Monoclonal Antibodies
          • Naked Monoclonal Antibodies
            • Rituximab (Rituxan)
            • Trastazumab (Herceptin)
            • Bevacizumab (Avastin)
            • Others
          • Conjugated Monoclonal Antibodies
            • Radiolabeled Antibodies
              • Ibrotumomab Tiuxetan (Zevalin)
            • Chemo labeled Antibodies
              • Brentixumab Vedotin (Adcetris)
              • Trastuzumab Emtansine (Kadcyla)
            • Bispecific Monoclonal Antibodies
              • Blinatumomab (Blincyto)
        • Cytokine Based Immunotherapy
          • Intron A
          • Proleukin
        • Cancer Vaccines
          • Preventive Vaccines
            • Gardasil
            • Cervarix
          • Treatment Vaccines
            • Sipuleucel-T (Provenge)
        • CAR-T Cell Therapy
          • Kymriah
          • Yescarta
      • By Cancer Type:
        • Non-Small Cell Lung Cancer
        • Acute Myeloid Leukemia
        • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
        • Multiple Myeloma
        • Breast Cancer
        • Ovarian Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Gastric Cancers
        • Glioblastoma
        • Head & Neck Cancers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Immune Checkpoint Inhibitors
          • CTL-4 Checkpoint Inhibitor
            • Iplimumab
          • PD-1 & PD-L1 Checkpoint Inhibitor
            • Nivolumab (Opdivo)
            • Atezolimumab (Tecentriq)
            • Pembrolizumab (Keytruda)
            • Avelumab (Bavencio)
            • Durvalumab (Imfinzi)
        • Monoclonal Antibodies
          • Naked Monoclonal Antibodies
            • Rituximab (Rituxan)
            • Trastazumab (Herceptin)
            • Bevacizumab (Avastin)
            • Others
          • Conjugated Monoclonal Antibodies
            • Radiolabeled Antibodies
              • Ibrotumomab Tiuxetan (Zevalin)
            • Chemo labeled Antibodies
              • Brentixumab Vedotin (Adcetris)
              • Trastuzumab Emtansine (Kadcyla)
            • Bispecific Monoclonal Antibodies
              • Blinatumomab (Blincyto)
        • Cytokine Based Immunotherapy
          • Intron A
          • Proleukin
        • Cancer Vaccines
          • Preventive Vaccines
            • Gardasil
            • Cervarix
          • Treatment Vaccines
            • Sipuleucel-T (Provenge)
        • CAR-T Cell Therapy
          • Kymriah
          • Yescarta
      • By Cancer Type:
        • Non-Small Cell Lung Cancer
        • Acute Myeloid Leukemia
        • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
        • Multiple Myeloma
        • Breast Cancer
        • Ovarian Cancer
        • Prostate Cancer
        • Colorectal Cancer
        • Gastric Cancers
        • Glioblastoma
        • Head & Neck Cancers
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • AstraZeneca, Plc
    • Bristol-Myers Squibb
    • Celgene Corporation
    • Eli Lilly and Company
    • Merck & Co.
    • Hoffmann-La Roche AG
    • Johnson & Johnson
    • Novartis International AG
    • AbbVie, Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • EMD Serono, Inc.
    • Gilead Sciences Inc.
    • Prometheus Therapeutics & Diagnostics
    • Aduro BioTech
    • Galena Biopharma
    • Bavarian Nordic
    • Celldex Therapeutics
    • ImmunoCellular Therapeutics
    • Incyte

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Cancer Type
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Immuno-Oncology Overview
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • PEST Analysis
    • PORTER’s Five Forces Analysis
    • Mergers & Acquisitions
    • Epidemiology
    • Research Update & Pipeline Analysis (For each drug category)
    • Major FDA Approvals & Product Launch Scenario (For each drug category)
    • Regulatory Scenario
    • Reimbursement Scenario
    • Immunotherapy Combination Therapies In Development
    • Adoptive Cell Transfer Therapies
  4. Global Immuno-Oncology Drugs Market, By Drug Type, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Immune Checkpoint Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • CTL-4 Checkpoint Inhibitor
          • Iplimumab
        • PD-1 & PD-L1 Checkpoint Inhibitor
          • Nivolumab (Opdivo)
          • Atezolimumab (Tecentriq)
          • Pembrolizumab (Keytruda)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • Naked Monoclonal Antibodies
          • Rituximab (Rituxan)
          • Trastazumab (Herceptin)
          • Bevacizumab (Avastin)
          • Others
        • Conjugated Monoclonal Antibodies
          • Radiolabeled Antibodies
            1. Ibrotumomab Tiuxetan (Zevalin)
          • Chemo labeled Antibodies
            1. Brentixumab Vedotin (Adcetris)
            2. Trastuzumab Emtansine (Kadcyla)
          • Bispecific Monoclonal Antibodies
            1. Blinatumomab (Blincyto)
    • Cytokine Based Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • Intron A
        • Proleukin
    • Cancer Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • Preventive Vaccines
          • Gardasil
          • Cervarix
        • Treatment Vaccines
          • Sipuleucel-T (Provenge)
    • CAR-T Cell Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • Kymriah
        • Yescarta
  5. Global Immuno-Oncology Drugs Market, By Cancer Type, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Non-Small Cell Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Acute Myeloid Leukemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Multiple Myeloma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Prostate Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Gastric Cancers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Glioblastoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Head & Neck Cancers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
  6. Global Immuno-Oncology Drugs Market, By Regions, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2016–2025
    • North America
      • Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of LATAM
    • Middle East
      • Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • EMD Serono, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Gilead Sciences Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Prometheus Therapeutics & Diagnostics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Aduro BioTech
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Galena Biopharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bavarian Nordic
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Celldex Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • ImmunoCellular Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Incyte
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 25 market data tables and 38 figures on "Immuno-Oncology Drugs Market - Global forecast to 2025”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.